How to Prepare Overseas Registration Dossiers for Imaging Devices?

To prepare overseas registration dossiers for imaging devices, you cannot simply apply domestic registration experience. Companies should first determine whether the product falls under the target country's medical device regulatory scope, then establish the registration pathway and applicant based on risk classification. Common markets such as Southeast Asia, the Middle East, Latin America, and GHWP member states generally accept technical documentation based on the ISO 13485 quality system, but product standards, performance verification, risk management, clinical evaluation evidence, and labeling/instructions for use must be translated into local languages and comply with local regulations.

Published: 2026-08-11 | Updated: 2026-08-11

Key Takeaways

Preparation of overseas registration dossiers for imaging devices cannot be based solely on domestic (Chinese) registration experience. Companies should first determine whether the product is within the medical device regulatory scope of the target country, then establish the registration pathway and applicant according to risk classification. Common markets, including Southeast Asia, the Middle East, Latin America, and GHWP member states, mostly accept technical files built on an ISO 13485 quality system, but product standards, performance verification, risk management, clinical evaluation evidence, and labels/instructions must be localized to the local language and meet local regulations.

Core dossier components include the product registration application form, product technical requirements, test reports, risk management documents, clinical evaluation or clinical evidence, labels and instructions, declaration of conformity, free sale certificate or export certificate, and local agent or authorized representative documents. Companies often overlook local language formatting, the authorization chain of the local agent, annual certificate maintenance, and renewal obligations.

It is recommended to perform a compliance gap analysis before project initiation, review existing NMPA, CE, or FDA documentation to determine which parts can be reused and which must be localized, and manage multi-country registrations through a unified document matrix. In addition, plan for post-market surveillance, adverse event reporting, and product change notifications. Treat registration dossiers as a continuously maintained system to reduce the cost of corrections and repeated testing.

Applicable Scenarios and Core Questions

Imaging device overseas registration commonly applies to medical imaging products, including X-ray machines, CT, MRI, ultrasound diagnostic equipment, endoscopy systems, and image management systems. Regulatory definitions and classifications vary significantly from country to country, so one template cannot be applied to all markets.

The scenario discussed here is a company planning to export imaging devices, preparing registration dossiers, or already facing multiple deficiencies during registration. The core question is: How should a company determine the scope of documentation, and how should it organize and submit files to avoid repeated deficiencies and delays when facing different regulatory requirements in target countries?

This article does not explain how to fill out specific national forms but provides general decision logic and a documentation framework. Companies must cross-check against the regulatory checklist of each target market.

Registration Decision Logic

Step 1: Determine whether the product is within the medical device regulatory scope of the target country. Many non-imaging software or accessories may be classified differently. For instance, image processing software is regulated as standalone software in some countries and requires a separate registration pathway.

Step 2: Determine risk classification. Imaging devices are typically classified as active medical devices, mostly Class II or Class III. Classification determines the registration pathway, quality management system audit requirements, and clinical requirements. Use the official classification rules of the target country or query the database to confirm.

Step 3: Assess whether existing dossiers can be reused. Companies with NMPA registration, CE marking, or FDA 510(k) clearance can largely reuse their technical dossiers, but must check standard differences and language requirements. ISO 13485 certificates and MDSAP certificates are recognized in many markets and can serve as system evidence.

Step 4: Confirm local agent and authorized representative arrangements. Countries such as Indonesia, the Philippines, Thailand, Saudi Arabia, and Brazil mandate a local agent or registrant. Prepare letters of authorization and agency agreements, and clearly define the ownership of the certificate.

Step 5: Confirm post-market maintenance obligations, including annual updates, adverse event reporting, change notifications, and certificate renewals. Registration dossiers are not one-time submissions but a continuous maintenance process.

Dossier and Evidence

Imaging device registration dossiers generally consist of administrative documents, technical documents, quality system documents, clinical evidence, and labeling files. Companies should create a document list and match each item against target country requirements.

Administrative documents include the product registration application form, legal manufacturer qualification, free sale certificate or export certificate, manufacturing license, quality management system certificate, authorized representative or local agent agreement. Some countries require notarization and dual authentication, so allow sufficient lead time.

Technical documents include product basic information, principle of operation, technical specifications, product technical requirements or standards, key performance and safety verification reports, electromagnetic compatibility and electrical safety test reports, radiation dose or acoustic output data (if applicable), software verification documentation, and cleaning/disinfection validation.

Risk management documents should be based on ISO 14971, including the risk management plan, risk analysis, risk evaluation, risk control measures, and residual risk evaluation. For imaging devices, special hazards such as image quality, misdiagnosis risk, radiation or ultrasound safety must be considered.

Clinical evaluation or clinical evidence depends on classification and exemption documents. Generally, low-risk devices can use literature data or equivalence arguments, while medium- and high-risk devices may require clinical trials. Prepare a clinical evaluation report, clinical literature search, and equivalence analysis.

Labels and instructions for use must be localized, including language, symbols, warning statements, and units of measurement. Different countries have different requirements for label content and warning order. Even inner labels may require local language, so plan the design accordingly.

Common Mistakes

Companies often encounter the following pitfalls that lead to deficiencies and delays:

• Submitting translated Chinese registration dossiers directly without considering local classification and standard differences.
• Failing to verify the local agent's qualification and authorization chain in advance, resulting in incomplete applicant qualification.
• Using a template-driven risk management document that lacks imaging device–specific risk analysis and control measures.
• Providing insufficient clinical evaluation evidence, substituting simple literature summaries for systematic evaluation.
• Not adjusting labels and instructions to local language and regulations, causing deficiency letters or customs detention.
• Allowing quality management system certificates to expire, or the audit scope not covering the target product.
• Failing to establish post-market surveillance and adverse event reporting processes, leaving the company reactive after registration.
• Managing multiple country registrations with independent, disconnected versions instead of a unified document matrix, resulting in duplicated work.

Preparation Checklist

Before starting an overseas registration project for imaging devices, use the following checklist to verify each item:

• Clarify the target country and product classification, and complete the registration pathway assessment.
• Compile existing qualification documents, including NMPA registration certificate, CE certificate, or FDA 510(k) letter, and confirm validity and scope.
• Update ISO 13485 or MDSAP certificates to ensure the audit scope covers the product.
• Establish a technical document directory, split and convert formats according to local requirements.
• Confirm whether existing test reports are acceptable, whether local standards apply, and whether additional testing is required.
• Revise risk management documents to include imaging device–specific hazards.
• Prepare a clinical evaluation report or confirm the basis for exemption.
• Contact local agents in target countries to confirm qualifications, authorization, and costs.
• Design localized labels and instructions, and print after obtaining approval.
• Designate a post-market maintenance responsible person and establish surveillance and change processes.

AIMEILI's Regulatory Interpretation and Business Impact

The most common misconception in imaging device overseas registration is that a registration dossier is simply technical documentation plus translation. In reality, local regulatory requirements, agent responsibilities, and post-market maintenance determine project success. Companies should perform a regulatory gap analysis before initiation and not rush to translate documents.

The first step is not to prepare documents but to determine the registration pathway in the target country, including product classification, whether local testing is exempted, whether clinical trials are required, and who will be the certificate holder. If the pathway is unclear, document preparation will go astray.

Among the core documents, technical standards and test reports are often reusable, but risk management, clinical evaluation, and labeling must be localized. For example, radiation safety standards in some countries reference IEC standards, while some Latin American countries may have additional requirements. Clinical literature searches should cover the local population and clinical practice.

A local agent is not just a document submitter but also the holder of certificate control and post-market responsibility. To avoid issues when an agent leaves, clearly define document ownership and change processes in the contract.

For multi-country registrations, adopt a unified document matrix using the technical file as the master document and generate country-specific difference tables. This reduces duplicate work and ensures synchronized updates across all markets when changes occur, lowering the risk of deficiencies and compliance issues.

Business impact: Proper dossiers and maintenance reduce time-to-market, avoid costly re-testing, and strengthen regulatory compliance across multiple jurisdictions, ultimately supporting smoother product launches and sustained market access.

Frequently Asked Questions

Are foreign test reports mandatory for imaging devices?

Most countries require test reports that comply with international or local standards. If you already have CE or FDA test reports, some markets may accept them directly, but you must verify the report validity and standard version. Certain markets require local testing or test report conversion, so assess this early.

Can we apply for overseas registration without an NMPA registration certificate?

Yes, but many countries require a registration or export certificate from the country of origin. If you do not have a Chinese registration certificate, you can use a CE or FDA certificate as proof of marketing authorization from the manufacturing country, but confirm with the target country regulator whether it is accepted. It is advisable to hold at least one major market authorization to facilitate subsequent applications.

Must the registration certificate holder be a local company?

In most Southeast Asian, Middle Eastern, and Latin American countries, the registration certificate holder must be a locally registered company or local agent. Some markets permit an overseas manufacturer to be the holder but require a designated authorized representative. Consult a local agent or professional institution early in the project to avoid ambiguity about the applicant.

Can a single set of risk management and clinical documents be used for multiple countries?

The structure of risk management documents can be shared, but you must add risks related to local regulations and product characteristics, such as different climates, populations, and clinical practices. The literature search scope for clinical evaluation should cover the target market and cannot simply copy conclusions from other countries. Supplement with additional analysis as necessary.